Arcus Biosciences (RCUS) FCF Margin (2017 - 2026)

Arcus Biosciences' FCF Margin history runs 10 years deep, the most recent figure standing at 811.76% for Q1 2026.

• In Q1 2026, FCF Margin fell 33676.0% year-over-year to 811.76%; the TTM figure through Mar 2026 stood at 206.36% (up 1067.0% YoY), while the FY2025 annual figure was 195.14%, down 12692.0% from the prior year.
• FCF Margin was 811.76% for Q1 2026 at Arcus Biosciences, down from 360.61% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 3627.78% in Q1 2022 to a low of 811.76% in Q1 2026.
• Historically, FCF Margin has averaged 66.61% across 5 years, with a median of 251.52% in 2022.
• The sharpest annual moves came in 2022 and 2023: FCF Margin jumped 435814 bps in 2022, then sank 403178 bps in 2023.
• A 5-year view of FCF Margin shows it stood at 205.88% in 2022, then tumbled by 150 bps to 514.29% in 2023, then advanced by 24 bps to 388.46% in 2024, then rose by 7 bps to 360.61% in 2025, then sank by 125 bps to 811.76% in 2026.
• The last three FCF Margin figures came in at 811.76% (Q1 2026), 360.61% (Q4 2025), and 373.08% (Q3 2025), per Business Quant data.